...
首页> 外文期刊>American journal of psychiatry >Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study
【24h】

Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study

机译:二甲双胍治疗首发精神分裂症妇女的抗精神病药性闭经和体重增加:一项双盲,随机,安慰剂对照研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: Data on the treatment of antipsychotic-induced amenorrhea, particularly when occurring with weight gain, are limited. The authors investigated the efficacy and safety of metformin in the treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia. Method: Eighty-four women (ages 18-40 years) with first-episode schizophrenia who suffered from amenorrhea during antipsychotic treatment were randomly assigned, in a double-blind study design, to receive 1000 mg/day of metformin or placebo in addition to their antipsychotic treatment for 6 months. The primary outcome measures were restoration of menstruation and change in body weight and body mass index (BMI). Secondary outcome measures were changes in levels of prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, and testosterone; in fasting levels of insulin and glucose; in LH/FSH ratio; and in insulin resistance index. Repeated mixed models with repeated-measures regression analyses and binary logistic regression were used in the analysis. Results: A total of 76 patients completed the 6-month trial. Significantly more patients in the metformin group (N=28, 66.7%) than in placebo group (N=2, 4.8%) resumed their menstruation. Among patients treated with metformin, BMI decreased by a mean of 0.93 and the insulin resistance index by 2.04. In contrast, patients who received placebo had a mean increase in BMI of 0.85. The prolactin, LH, and testosterone levels and LH/FSH ratio decreased significantly in the metformin group at months 2, 4, and 6, but these levels did not change in the placebo group. Conclusions: Metformin was effective in reversing antipsychotic-induced adverse events, including restoration of menstruation, promotion of weight loss, and improvement in insulin resistance in female patients with schizophrenia.
机译:目的:治疗抗精神病性闭经的数据有限,尤其是在体重增加时。作者研究了二甲双胍在抗精神病药引起的闭经和体重增加的女性首发精神分裂症患者中的疗效和安全性。方法:在一项双盲研究设计中,随机分配了八十四名年龄在18至40岁之间的精神分裂症首发精神分裂症的妇女,他们在抗精神病药物治疗期间患有闭经,除了每天接受1000 mg的二甲双胍或安慰剂治疗外他们进行了6个月的抗精神病治疗。主要结果指标是恢复月经以及体重和体重指数(BMI)的变化。次要结果指标是催乳素,促黄体生成激素(LH),促卵泡激素(FSH),雌二醇和睾丸激素水平的变化;空腹胰岛素和葡萄糖水平; LH / FSH比;以及胰岛素抵抗指数。在分析中使用具有重复测量回归分析和二元逻辑回归的重复混合模型。结果:总共76位患者完成了为期6个月的试验。二甲双胍组(N = 28,66.7%)比安慰剂组(N = 2,4.8%)恢复月经的患者多得多。在接受二甲双胍治疗的患者中,BMI平均下降0.93,胰岛素抵抗指数下降2.04。相反,接受安慰剂的患者的BMI平均增加0.85。二甲双胍组在第2、4和6个月时催乳素,LH和睾丸激素水平以及LH / FSH比显着下降,但在安慰剂组中这些水平没有变化。结论:二甲双胍可有效逆转抗精神病药所致的不良事件,包括恢复月经,促进体重减轻和改善女性精神分裂症患者的胰岛素抵抗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号